Tibet Rhodiola Pharmaceutical Holding Co

SSE:600211

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Tibet Rhodiola Pharmaceutical Holding Co's stock price target?

Not Available

Tibet Rhodiola Pharmaceutical Holding Co doesn't have any price targets made by Wall Street professionals.

What is Tibet Rhodiola Pharmaceutical Holding Co's Revenue forecast?

Projected CAGR

10%

For the last 13 years the compound annual growth rate for Tibet Rhodiola Pharmaceutical Holding Co's revenue is 8%. The projected CAGR for the next 3 years is 10%.

What is Tibet Rhodiola Pharmaceutical Holding Co's Operating Income forecast?

Projected CAGR

-20%

For the last 13 years the compound annual growth rate for Tibet Rhodiola Pharmaceutical Holding Co's operating income is 44%. The projected CAGR for the next 7 years is -20%.

What is Tibet Rhodiola Pharmaceutical Holding Co's Net Income forecast?

Projected CAGR

3%

For the last 13 years the compound annual growth rate for Tibet Rhodiola Pharmaceutical Holding Co's net income is 35%. The projected CAGR for the next 3 years is 3%.